Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Direvo Introduces BluCon™

Published: Friday, November 16, 2012
Last Updated: Friday, November 16, 2012
Bookmark and Share
Conversion of non-food biomass to biofuel and chemical building blocks.

Direvo Industrial Biotechnology GmbH is commercializing its BluCon™ platform for complete, one-step conversion of non-food feedstocks to carbohydrates used in the production of fuels and chemicals.

In the recent years Direvo has undertaken a huge research program identifying a portfolio of proprietary microorganisms, which enable the lowest cost production of valuable chemicals from non-food biomass.

The BluCon™ platform is extremely flexible both for the type of feedstock and the resultant high value fuels and chemicals produced.

BluCon™ converts various non-food biomass ranging from grasses and straw to agricultural and wood residues and can therefore be applied around the globe.

From an end product perspective, BluCon™ delivers transportation fuels like ethanol or chemical building blocks like lactic acid.

“After two years of extremely hard work, we are very excited to use our BluCon™ platform in solving global raw material supply and environmental concerns. Our technology will capture a significant share of the developing bio-based economy”, CEO Jorg Riesmeier explains.

BluCon™ technology platform is a so-called second generation biomass conversion technology. Contrary to first generation technology there is no need to use food feedstocks.

The switch from a fossil-based to a bio-based economy is driven by global warming and by the finite nature of fossil fuels and sustainability.

The gradual switch requires many new technologies at various levels. On a global basis, the demand for transportation fuels and chemical building blocks will continue to increase for foreseeable future.

By 2050 the World Energy Council (WEC) forecasts that global fuel demand could increase as much as 82% compared to 2010 levels. In combination with dwindling public acceptance of fossil-based raw materials, this will lead to a high need for biofuels and bioplastics.

Direvo Industrial Biotechnology GmbH is the only German company and one of very few in Europe developing such a technology.

With decades of experience in “directed evolution” Direvo is perfectly positioned for the final steps of process development along with a network of commercialization partners. These are being carried out partly in house and partly in collaboration with global partners from industry and academia.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

European and US Cellulase Patents Granted to Direvo
Granted patents describe improved cellulase enzymes having CBH II activity.
Wednesday, May 22, 2013
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!